Increasing usage of medicines, and the associated amount being spent on them, have become central issues in health policy and international trade discussions. The policies many countries are pursuing are reshaping access, usage and pricing, with implications for hundreds of millions of patients globally. In addition, the continuation of historic trends in disease treatment and adoption of innovation result in a steady rise in the level of medicine use globally.

Established patterns of spending and usage continue to highlight differences in access and pricing across countries. The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity. In addition, the mix of spending growth between volume-driven growth and mix-driven changes in the cost of therapy are showing most geographies shifting to more expensive therapies, reflecting the broader availability and patient access to medicines with higher costs.

This mix of spending growth between volume-driven growth and mix-driven changes in the cost of therapy are showing most geographies shifting to more expensive therapies, reflecting the broader availability and patient access to medicines with higher clinical value.

As these dynamics have distinct variations around the world, this session includes a panel discussion with IQVIA colleagues in key regions.

The webinar will look closely at:

• Outlook for the use of medicines and drivers
• Therapy area drivers of medicine use and spending
• Spending and growth by regions and key countries